Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
First Claim
1. A method for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness, or at risk for same, by administering an analgesic composition comprising a sub-analgesic dosage of a μ
- -opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or a pharmaceutically acceptable salt thereof, and a sub-analgesic dosage of oxycodone, a κ
2-opioid agonist, or a pharmaceutically acceptable salt thereof, wherein the method achieves an analgesic effect in the patient to which the composition is administered.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to methods for reducing the risk associated with the administration of opioid analgesics in patients diagnosed or undiagnosed with respiratory illness by administering an analgesic composition comprising a sub-analgesic dosage of a μ-opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or a pharmaceutically acceptable salt thereof, and a sub-analgesic dosage of oxycodone which is a κ2-opioid agonist or a pharmaceutically acceptable salt thereof.
19 Citations
23 Claims
-
1. A method for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness, or at risk for same, by administering an analgesic composition comprising a sub-analgesic dosage of a μ
- -opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or a pharmaceutically acceptable salt thereof, and a sub-analgesic dosage of oxycodone, a κ
2-opioid agonist, or a pharmaceutically acceptable salt thereof, wherein the method achieves an analgesic effect in the patient to which the composition is administered. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
- -opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or a pharmaceutically acceptable salt thereof, and a sub-analgesic dosage of oxycodone, a κ
-
20. A method of minimizing the risk of developing sleep apnea in susceptible patients treated for the alleviation or prevention of pain, wherein the method comprises the step of administering an analgesic composition comprising a sub-analgesic dosage of a μ
- -opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or a pharmaceutically acceptable salt thereof, and a sub-analgesic dosage of oxycodone, a κ
2-opioid agonist, or a pharmaceutically acceptable salt thereof. - View Dependent Claims (21)
- -opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or a pharmaceutically acceptable salt thereof, and a sub-analgesic dosage of oxycodone, a κ
-
22. An analgesic composition comprising a sub-analgesic dosage of morphine, a μ
- -opioid agonist, and a sub-analgesic dosage of oxycodone, a κ
2-opioid agonist, or pharmaceutically acceptable salts thereof, wherein the composition, upon administration to a patient, achieves an analgesic effect in that patient, equivalent to the analgesic effect that would result from the administration of an analgesic composition consisting of about twice the mass of morphine alone.
- -opioid agonist, and a sub-analgesic dosage of oxycodone, a κ
-
23. An analgesic composition comprising a sub-analgesic dosage of morphine, a μ
- -opioid agonist, and a sub-analgesic dosage of oxycodone, a κ
2-opioid agonist, or pharmaceutically acceptable salts thereof, wherein the composition, upon administration to a patient, achieves an analgesic effect in that patient equivalent to the analgesic effect that would result from the administration of an analgesic composition consisting of about 1.5 times the mass of oxycodone alone.
- -opioid agonist, and a sub-analgesic dosage of oxycodone, a κ
Specification